A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase Ib Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05698303
• Other study ID #: CT103AA001
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: May 8, 2023
• Est. completion date: January 15, 2026

Study information

• Verified date: December 2022
• Source: Nanjing IASO Biotherapeutics Co.,Ltd
• Contact: Robert Z. Orlowski, M.D., Ph.D.
• Phone: 713-792-2860
• Email: rorlowsk[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is a dose expansion, open-label, phase Ib study to evaluate the safety, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of CT103A in patients with relapsed/refractory multiple myeloma.

Description:

A total of at least 12 subjects are planned to be enrolled in this study. Each subject will proceed through the following study periods:

• Screening

• Leukapheresis

• Bridging therapy (at the discretion of the investigator)

• Pre-lymphodepletion assessment

• Lymphodepleting chemotherapy

• Pre-infusion Assessment

• CT103A infusion (Day 0)

• 28-Day safety evaluation period

• Post-treatment follow-up period (Day 29 through year 2)

All the subjects will be followed for safety and efficacy until disease progression, initiation of subsequent anti-myeloma therapy, withdrawal, death, loss to follow-up, study completion, end of study, or study termination, whichever occurs first. Subjects except those that are deceased, lost to follow-up, or have withdrawn their ICF will enter the long-term follow-up (LTFU) under a separate protocol for at least 15 years.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 12
• Est. completion date: January 15, 2026
• Est. primary completion date: May 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. = 18 years of age.

2. Documented diagnosed with multiple myeloma according to the IMWG diagnostic criteria.

3. Have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulator-based chemotherapy, and an anti-CD38 therapy (prior exposure can be from different monotherapy or combination regimens), or are refractory to both a proteasome inhibitor and an immunomodulatory agent (i.e., double refractory).

4. Documented disease progression during or within 12 months of the most recent anti-myeloma treatment (except for subjects who received CAR-T as last-line therapy).

5. For subjects with previous BCMA-targeted therapy, the best response should be at least PR, and positive BCMA expression on tumor cells by immunohistochemistry (IHC) or flow cytometry is required before enrollment.

6. The presence of measurable lesion according to IMWG 2016 criteria at screening as determined by any of the following criteria:

• Serum M-protein level =1.0 g/dL or urine M protein level = 200 mg/24 h; or

• Light chain multiple myeloma without measurable lesions in serum or urine:

Involved serum free light chain = 10 mg/dL and abnormal serum ?/? free light chain ratio.

7. ECOG score of 0 or 1 (refer to Appendix 2)

8. Subjects must have appropriate organ function and meet all the following laboratory test results prior to enrollment:

• Hematology: Absolute neutrophil count (ANC) = 1×109/L (supportive growth factor is permitted, but must be without supportive treatment within 7 days before the laboratory test); absolute lymphocyte count (ALC) =0.3×109/L; platelet count =50×109/L (must be without supportive blood transfusion within 7 days before the laboratory test); hemoglobin =80 g/L (without transfusion of red blood cells [RBC] within 7 days before the laboratory test; the use of recombinant human erythropoietin is permitted).

• Liver function: Alanine transaminase (ALT) and aspartate transaminase (AST) = 2.5×upper limit of normal (ULN); serum total bilirubin = 1.5×ULN except with known Gilbert's syndrome who have serum bilirubin = 3×ULN.

• Renal function: Creatinine clearance (CrCl) calculated using the Cockcroft-Gault formula = 40 ml/min.

• Coagulation function: Fibrinogen =1.0 g/L; activated partial thromboplastin time =1.5× ULN, prothrombin time (PT) =1.5× ULN.

• Corrected serum calcium =11 mg/dL

• Oxygen saturation (by Fingertip Pulse Oximeter) =92%.

• Left ventricular ejection fraction (LVEF) =45%.

9. Female subjects of childbearing potential or male subjects with a partner of childbearing potential agree to use effective contraception methods from screening and continued during study treatment until one year after the last dose.

10. The subject must personally sign an informed consent form approved by the ethics committee in writing.

Exclusion Criteria:

1. Subjects with graft versus host disease (GVHD) or those requiring long-term use of immunosuppressants.

2. Received autologous hematopoietic stem cell transplant (Auto-HSCT) within 12 weeks before apheresis or received prior allogeneic hematopoietic stem cell transplant (Allo-HSCT).

3. Received prior anti-myeloma therapies as follows:

• Treatment with monoclonal antibodies within 21 days prior to apheresis, or

• Treatment with cytotoxic chemotherapy or proteasome inhibitor within 14 days prior to apheresis, or

• Treatment with immunomodulator within 7 days prior to apheresis, or

• Anti-myeloma therapies other than those described above within 14 days or at least 5 half-lives (whichever is shorter) prior to apheresis.

4. Use of glucocorticoids (defined as prednisone or equivalent > 20 mg/day) at a therapeutic dose within 7 days prior to apheresis. Physiologic replacement, topical, and inhalation steroids are permitted, nevertheless.

5. Severe heart disease: Including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive cardiac failure (New York Heart Association [NYHA] classification grade = III), severe arrhythmia.

6. Unstable systemic diseases judged by the investigator: Including but not limited to severe liver, kidney or metabolic diseases requiring therapy.

7. Malignancies other than multiple myeloma within 5 years prior to screening, excluding adequately treated carcinoma in situ of cervix, basal or squamous epithelial cell skin cancer, localized prostate cancer post radical operation, ductal carcinoma in situ of the breast post radical operation.

8. History of organ transplant.

9. Suspected or confirmed central nervous system involvement.

10. Plasma cell leukemia at the time of screening (>2.0×109/L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary AL amyloidosis.

11. Major surgery within 2 weeks prior to apheresis, or planned surgery within 2 weeks after study treatment administration (subjects who plan to receive surgery under local anesthesia are permitted to be enrolled in this study).

12. Treated with other interventional clinical investigational products within 1 month before signing the informed consent form (ICF).

13. Evidence of serious active viral, bacterial, or uncontrolled systemic fungal infection prior to apheresis.

14. Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA in peripheral blood; positive hepatitis C virus (HCV) antibody with positive HCV RNA in peripheral blood; positive human immunodeficiency virus (HIV) antibody; positive cytomegalovirus (CMV) DNA; positive syphilis test.

15. Pregnant or breastfeeding women or planning to become pregnant while enrolled in this study or within 1 year after receiving study treatment.

16. Stroke, seizure or psychosis within 6 months of signing ICF.

17. Non-hematological toxicities from previous anti-myeloma therapy have not recovered to baseline or grade =1 (NCI-CTCAE v5.0, except for alopecia and grade 2 peripheral neuropathy).

18. Any issue that would impair the ability of the subject to receive or tolerate the planned treatment, to understand informed consent or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3? domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.

Locations

Country	Name	City	State
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing IASO Biotherapeutics Co.,Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	CAR-positive cell counts in peripheral blood.	CAR-positive cell counts in peripheral blood will be measured and reported.	Up to 2 years after CT103A infusion.
Other	Presence of human anti-CAR antibodies	The titer of confirmed positive anti-CAR antibodies in peripheral blood will be measured and reported.	Up to 2 years after CT103A infusion.
Other	Presence of RCL in peripheral blood.	Presence of RCL in peripheral blood will be measured and reported.	Up to 2 years after CT103A infusion.
Primary	Incidence and severity of adverse events	An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0, with the exception of cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).	Up to 2 years after CT103A infusion.
Primary	Incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)	CRS and ICANS will be evaluated according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading.	Up to 2 years after CT103A infusion.
Primary	Number of participants with laboratory abnormalities	Number of participants with laboratory abnormalities will be reported.	Up to 2 years after CT103A infusion.
Secondary	Overall response rate (ORR)	The proportion of subjects who achieved at least a PR or better as defined by the International Myeloma Working Group (IMWG) response criteria.	Up to 2 years after CT103A infusion.
Secondary	Progression-free survival (PFS)	Duration from the date of CT103A infusion to the date of first documented evidence of progressive disease or death due to any cause.	Up to 2 years after CT103A infusion.
Secondary	Overall survival (OS)	Duration from the start of CT103A treatment to subject death (due to any cause).	Up to 2 years after CT103A infusion.
Secondary	Duration of response (DOR)	Duration from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria.	Up to 2 years after CT103A infusion.
Secondary	Time to response (TTR)	Time interval from the date of CT103A infusion to the date of initial documentation of a response (PR or better)	Up to 2 years after CT103A infusion.
Secondary	Time to complete response (TTCR)	Time interval from the date of CT103A infusion to the date of initial documentation of a complete response (CR) or stringent complete response (sCR).	Up to 2 years after CT103A infusion.
Secondary	MRD response assessment	The proportion of subjects achieved MRD-negativity.	Up to 2 years after CT103A infusion.
Secondary	The duration of MRD-negativity	The duration of MRD-negativity is defined as the time interval between the first occurrence of negative MRD after infusion and the first reversal of negative MRD results to positive.	Up to 2 years after CT103A infusion.
Secondary	CAR transgene level in peripheral blood.	The CAR transgene level in peripheral blood both pre- and post- CT103A infusion will be measured and reported.	Up to 2 years after CT103A infusion.
Secondary	Soluble BCMA (sBCMA) in peripheral blood.	The level of sBCMA in peripheral blood will be measured and reported.	Up to 2 years after CT103A infusion.